187
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

The relationship between serum interleukin-1β, interleukin-6, interleukin-8, interleukin-10, tumor necrosis factor-α levels and clinical features in essential tremor

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1143-1149 | Received 06 Jun 2020, Accepted 30 Nov 2020, Published online: 02 Jan 2021
 

Abstract

Background

In recent years, there has been discussion that essential tremor (ET) might be a neurodegenerative disease. Indicators of inflammation are considered as possible biomarkers of neurodegeneration. In this connection, the aim of our study was to identify the relationship between serum inflammation markers and clinical features in ET, including the severity of tremor, cognitive decline, depression.

Methods

The serum interleukin-1β (IL-1β), IL-6, IL-8, IL-10, and tumor necrosis factor-α (TNF-α) levels were measured in 90 ET patients and 90 healthy control people of the corresponding age and gender. Fahn-Tolosa-Marin scale was used for the severity of the tremor. Cognitive function was assessed using the MoCA. Affective symptoms were measured by the Beck Depression Inventory.

Results

ET patients had significantly lower serum TNF-α (p < 0.01) but higher serum IL-8 (p < 0.02) and IL-10 (p < 0.01) levels compared to the control patients. The severity of tremor positively correlated with the serum IL-8 level, R = 0.3 (p < 0.01). The serum IL-6 level was higher in ET patients with cognitive impairment compared with normal cognitive ability (p < 0.01). ROC analysis showed that an IL-8 level of 4 pg/ml and higher related with a high risk of severe tremor in ET (AUC-ROC = 0.761).

Conclusions

Our findings demonstrate that neuroinflammation makes a certain contribution to the development of ET.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.